Brief: AbCellera Receives Authorization From Health Canada To Initiate The Phase 1 Clinical Trial Of Abcl635 For Vasomotor Symptoms Due To Menopause
May 14 (Reuters) - Abcellera Biologics Inc ABCL.O: ABCELLERA RECEIVES AUTHORIZATION FROM HEALTH CANADA TO INITIATE THE PHASE 1 CLINICAL TRIAL OF ABCL635 FOR VASOMOTOR SYMPTOMS DUE TO MENOPAUSE ABCELLERA RECEIVES AUTHORIZATION FROM HEALTH CANADA TO INITIATE THE PHASE 1 CLINICAL TRIAL OF ABCL635 FOR VASOMOTOR SYMPTOMS DUE TO MENOPAUSE ABCELLERA BIOLOGICS INC - PHASE 1 TRIAL FOR ABCL635 EXPECTED TO START IN Q3 2025 Source text: ID:nBw90vhPga Further company coverage: ABCL.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on AbCellera Biologics
See all newsAbCellera Biologics Inc. reports results for the quarter ended September 30 - Earnings Summary
Canada's AbCellera Q3 revenue beats analyst estimates
Factbox: Pharma sector doubles down on AI to slash costs, timelines
U.S. STOCKS ON THE MOVE-Tapestry, Cisco, Sandisk
U.S. STOCKS ON THE MOVE-EnerSys, Netflix, Salesforce